BI drug gets priority review

Share this article:

The FDA bestowed priority review status on Boehringer Ingelheim's experimental idiopathic pulmonary fibrosis treatment nintedanib. The treatment also has orphan drug status—the progressive and fatal lung disease is a rare condition which affects around 132,000 patients in the US.

Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.